Skip to main content
Jatin Shah, MD, Oncology, Houston, TX

JatinShahMD

Oncology • Houston, TX

Associate Professor

Join to view full profile

Dr. Shah is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Shah's full profile

Already have an account?

  • Office

    1515 Holcombe Blvd
    Houston, TX 77030
    Phone+1 713-792-6161

Education & Training

  • University of Alabama Medical Center
    University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationResidency, Internal Medicine, 2001 - 2004
  • Ohio State University College of Medicine
    Ohio State University College of MedicineClass of 2001

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2007 - 2025

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
    Jatin Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)
    Jatin Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome
    Jatin J. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Updated Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myel... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-1287, an Investigational Oral CDK9 Inhibitor for the Treatment of Ewing Sarcoma
    Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-1287, an Investigational Oral CDK9 Inhibitor for the Treatment of Ewing SarcomaApril 10th, 2023
  • Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-3654, an Investigational Oral Inhibitor of PIM Kinases for the Treatment of Myelofibrosis
    Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-3654, an Investigational Oral Inhibitor of PIM Kinases for the Treatment of MyelofibrosisJune 8th, 2022
  • Rakesh Roshan on His Battle with Cancer: I Was Sure I Had Cancer Even Before the Reports Came
    Rakesh Roshan on His Battle with Cancer: I Was Sure I Had Cancer Even Before the Reports CameOctober 19th, 2019
  • Join now to see all

Dr. Jatin Shah, Dr. Jatin Shah, MD, Dr. J Shah